ACORN CAPITAL MICRO OPPORTUNITIES FUND


INVESTMENT UPDATE
June 2025



Top 5 Stocks

Company	
Aroa Biosurgery	Health Care
EROAD	Tech
Findi	Financials
Meeka Metals	Resources
Vysarn	Industrials
Weight Top 5	18.5%

Sector Exposures



Fund Overview

APIR Code	ACQ4764AU
Benchmark	S&P ASX Emerging Companies Accumulation Index
Distributions	Annual
Management Fee	1.20%
Incentive Fee	20% above benchmark
Highwater mark	Yes
Responsible Entity	Evolution Trustees Ltd
Pricing frequency	Daily
Min. investment	\$20,000

Ratings*

Lonsec "Recommended"



Contact: Phil Morgan Phone: 0421 915 040

philmorgan@acorncapital.com.au

Commentary 1

The portfolio returned 10.1% in the June quarter, outperforming the S&P/ASX Emerging Companies Index which return 2.2%.

The portfolio generated positive relative outperformance in the Healthcare, IT, Communication Services and Resources sectors with only modest relative underperformance in the Industrials and Consumer Staples sectors.

The benchmark's return for the quarter was driven by solid positive returns across most sectors, particularly Industrials and Financials, with only the Healthcare sector (-14.7%) being a notable drag on the index. Several larger capitalised stocks like Mayne Pharma (-30.8%, attempted withdrawal of takeover offer for company) and Monash IVF (-37.9%, clinical operations issues) experienced company specific issues which drove the negative sector returns rather than any macro or top-down influence.

Over the quarter the portfolio generated positive portfolio performance across most sectors, in particular the Communications (Superloop +42.7%), Materials ex-Resources (Amaero +37.9%) and Healthcare (Amplia Therapeutics +179%, Aroa Biosurgery +36.7%) sectors. The Energy sector was the only notable negative contributor, returning -5.2% over the quarter.

At the end of the quarter the portfolio held 66 stocks with the top 10 representing 32.5% and a cash holding of 8.8%.

Performance

			FYTD %				Since incept. % pa
Micro Opportunities Fund ²	4.27	10.06	13.02	13.02	9.48	9.74	11.16
Benchmark	-0.41	2.17	8.78	8.78	7.13	12.65	13.51
Alpha	+4.69	+7.89	+4.24	+4.24	+2.35	-2.91	-2.35

Quarterly Contributors/Detractors

Contributors				
Company				
Amplia Therapeutics	Health Care	+1.86		
AMA	Discretionary	+1.82		
EROAD	Tech	+1.75		

Detractors				
Company				
City Chic Collective	Discretionary	-0.46		
Rox Resources	Resources	-0.64		
Quickfee	Financials	-0.98		

^{1.} Commentary for quarter of June 2025 2. Net performance is based on redemption price for the period, after all fees and costs. Assumes all distributions are reinvested.










QUARTERLY UPDATE June 2025





Fund Commentary 4

Notable positive portfolio contributors during the quarter include:

Amplia Therapeutics (+179%) announced very encouraging data from its Phase 1b/2a ACCENT trial in advanced pancreatic cancer including 2 complete responses, an extremely rare outcome in this very difficult to treat indication. While early in its clinical development, results so far have greatly exceeded expectations and with 20 patients still on trial we look forward to assessing final trial results expected later in 2025.

AMA (+81.1%) having significantly reducing balance-sheet risk the company provided a Q325 update that showed the turnaround taking hold: normalised pre-AASB 16 EBITDA jumped 97 % year-on-year to \$21.1 m, with margins nudging 9 % and FY25 guidance lifted to \$58–62 m. The combination of a cleaner capital structure and sharply improving earnings drove the sharp re-rating.

EROAD (+50.3%) The company reported its FY25 results and provided a FY26 outlook statement that showed increasing operating leverage and free cashflow confirming the turnaround is firmly in place. Constellation Software also exited its 10 % stake, removing a long-standing takeover-bid overhang, clearing the path for a valuation re-rating.

Notable negative portfolio contributors during the month included:

Quickfee (-44.9%) fell after it announced a provision for a potential credit impairment in its USA business which negatively impacted full year EBTDA guidance. A capital raise was completed in June to shore up the balance sheet and enable orderly business **operations**.

Rox Resources (-18.4%) is developing the Youanmi Gold Project in Western Australia. In May, the company announced a two-tranche A\$40 m institutional placement (-15 % to the prior close). The raise capped near-term upside, and the weakness persisted as the second tranche settled on 30 June. Despite the recent weak performance, we remain positive on the stock.

City Chic Collective (-31.7%) City Chic Collective was down because of tariff impact uncertainties on their USA operations which contribute about a quarter of company revenues. While the USA business faces some shorter-term uncertainties the Australian and New Zealand business is growing strongly (17% in 2HFY25TD).

1. Stage of development as defined by Acorn Capital. 2. Rounding may result in weight not totalling 100% 3. Number of holdings as at month end date, 4. Commentary for June quarter 2025

This report is published by Acorn Capital Limited ("Acorn") ABN: 51 082 694 531, AFSL: 227605 and is general information only and is not intended as an offer or solicitation with respect to the purchase or sale of any securities by Acorn or the responsible entity and Issuer. Evolution Trustees Limited ("Evolution") ABN: 29 611 839 519 AFSL: 486217 is the responsible entity and Issuer of the Acorn Capital Micro Opportunities Fund (the Fund) ARSN: 673 344 833 Acorn is the investment or fund manager of the Fund. This report does not take into account the investment objectives, financial situation or needs of any particular person. Investors should obtain personal financial advice based on their own particular needs and circumstances before making any investment decision. Any person considering investing, holding or disposing of units in the Fund should review the Product Disclosure Statement for the Fund dated 15 December 2023, Reference Guide, Target Market Determination and any other material published by Acorn. This information is available at www.acorncapital.com.au. Evolution and Acorn do not guarantee repayment of capital or any particular rate of return from the Fund. Past performance is no guarantee furture performance. Investment returns have been calculated in accordance with normal industry practice utilising movements in unit price and assuming reinvestment of all distributions of income and realised profits. The information is current at the date of publication, and whilst all care has been taken in its preparation, neither Acorn nor Evolution gives any representation or warranty as to the reliability, completeness or accuracy of the information contained in this report. Statements in this report have been obtained from and are based upon sources that Acorn believes to be reliable, however Acorn does not guarantee their accuracy, and any such information may be incomplete or condensed. All opinions and estimates included in this report are subject to change without notice. Not to be reproduced without

^{*}The rating issued 10/2024 is published by Lonsec Research Pty Ltd ABN 11 151 658 561 AFSL 421 445 (Lonsec). Ratings are general advice only, and have been prepared without taking account of your objectives, financial situation or needs. Consider your personal circumstances, read the product disclosure statement and seek independent financial advice before investing. The rating is not a recommendation to purchase, sell or hold any product. Past performance information is not indicative of future performance. Ratings are subject to change without notice and Lonsec assumes no obligation to update. Lonsec uses objective criteria and receives a fee from the Fund Manager. Visit lonsec.com.au for ratings information and to access the full report. © 2025 Lonsec. All rights reserved